May 11, 2022
UNC Neurology’s May 2022 Newsletter is Out
Read the latest news from the UNC Department of Neurology.
Category: Neurology
May 10, 2022
UCB Presents Efficacy, Safety Results for Zilucoplan, Rozanolixizumab for Generalized Myasthenia Gravis
James F. Howard, MD, Distinguished Professor of Neuromuscular Disease, Professor of Neurology, Medicine and Allied Health in the UNC School of Medicine, was lead investigator in the Phase 3 clinical trial of zilucoplan.
April 29, 2022
FDA Approves Treatment for Myasthenia Gravis After Phase III Study Led by James Howard, MD
James F. Howard, Jr, MD, in the UNC Department of Neurology is the lead primary investigator in the CHAMPION-MG trial for Ultomiris (ravulizumab-cwvz) as a treatment for adults with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive, which represents 80% of people living with the disease.
April 29, 2022
Scientists Detail Brain Dynamics Implicated in Neurological Conditions
UNC School of Medicine researchers led by Ian Shih, PhD, used fMRI and a genetic mouse model to study the effects of a neurotransmitter on brain network functional connectivity, a dynamic process crucial for human health and behavior.
April 6, 2022
Interim Data Suggest Long-term Treatment with VYVGART Provides Improvement in Generalized Myasthenia Gravis Disease Scores
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the ADAPT+ trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.
March 29, 2022
UNC Physical Medicine and Rehabilitation Spring Newsletter is Out
The department's spring newsletter includes stories on the UNC COVID Recovery Clinic, views from the new Acute Inpatient Rehab center in Hillsborough, and new faculty members and advanced practice providers.
March 25, 2022
Felix Elected to AAN Section Leadership
Ana C. G. Felix, MBBCh, FAAN, has been elected as the American Academy of Neurology's 2022-2023 Vice Chair of the AB Baker Section on Neurological Education.
March 11, 2022
Statts Named Department of Neurology Interim Associate Chair for Administration
Robert Statts will begin his work in the interim role on March 17.
February 15, 2022
Phase 3 Study Results Show Positive Data in Treatment of Myasthenia Gravis with Zilucoplan
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was lead investigator in UCB's RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults.
February 3, 2022
Smith Named Vice Dean of the UNC Gillings School of Global Public Health
Robert Smith III, PhD, currently is associate chair for administration in the Department of Neurology. He will begin his new role on Feb. 28.
January 19, 2022
New Alzheimer’s Disease Research Forum to Launch in January
All trainees (fellows, postdocs, junior faculty, residents, research associates, etc.) interested in Alzheimer’s disease and related dementias (ADRD) are invited to attend the inaugural meeting of the ADRD IDEAS Forum to be held monthly by the Duke-UNC Alzheimer's Disease Research Center. The forum will be directed towards early-career investigators from Duke, UNC-CH, ECU, NCCU, and UNC-Pembroke.
January 3, 2022
FDA Approves New Drug to Treat Generalized Myasthenia Gravis
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.